Table 4.
Delphi round 1 responses
| Component | Inclusion of standard on this component | Consensus (% rating as extremely or very important, i.e., ≥ 75%) | ||||
|---|---|---|---|---|---|---|
| Extremely important | Very important | Somewhat important | Not so important | Not at all important | ||
| Identification | ||||||
| Fragility fracture | 22 | 3 | 0 | 0 | 0 | Yes (100%) |
| Risk factors for osteoporosis | 12 | 10 | 2 | 0 | 0 | Yes (92%) |
| Medicines associated with bone loss/fracture risk | 7 | 15 | 3 | 0 | 0 | Yes (88%) |
| Medical conditions associated with bone loss/fracture risk | 5 | 16 | 4 | 0 | 0 | Yes (84%) |
| Investigation | ||||||
| Biochemistry | 5 | 11 | 8 | 1 | 0 | No |
| BMD testing | 8 | 9 | 8 | 0 | 0 | No |
| Risk assessment tools | 12 | 9 | 3 | 1 | 0 | Yes (84%) |
| Vertebral fracture assessment | 14 | 5 | 4 | 1 | 0 | Yes (79%) |
| Falls risk assessment | 9 | 13 | 3 | 0 | 0 | Yes (88%) |
| Specialist referral | 4 | 11 | 8 | 2 | 0 | No |
| Information for patients | 14 | 7 | 4 | 0 | 0 | Yes (84%) |
| Intervention | ||||||
| Indications—see Table 5 | N/A | |||||
| Pharmacological | 10 | 12 | 3 | 0 | 0 | Yes (88%) |
| Non-pharmacological | 4 | 16 | 4 | 1 | 0 | Yes (80%) |
| Side effects | 6 | 15 | 3 | 1 | 0 | Yes (84%) |
| Monitoring effect | 11 | 11 | 3 | 0 | 0 | Yes (88%) |
| Duration | 13 | 8 | 4 | 0 | 0 | Yes (84%) |
| Adherence | 8 | 12 | 3 | 2 | 0 | Yes (80%) |
| Falls programs | 5 | 13 | 6 | 0 | 0 | No |
| Integration | ||||||
| Long-term management plans | 11 | 9 | 4 | 1 | 0 | Yes (80%) |
| Quality | ||||||
| Adherence to guideline-based care | 10 | 12 | 2 | 1 | 0 | Yes (88%) |
Respondents’ priority ratings for each of the key components identified in existing clinical practice guidelines. Consensus was defined as a rating of extremely important or very important by at least 75% of respondents